216.73.216.231===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'pdsb'---select * from `0-usmeigara` WHERE code='pdsb'
aaＰＤＳ　バイオテクノロジー

pdsb
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
臨床段階のバイオ医薬品会社であるPDS Biotechnology Corporationは、多機能がん免疫療法の開発に焦点を当てています。同社は、前立腺癌および乳がんを治療するためのPDS0102 T細胞受容体ガンマ代替リーディングフレームタンパク質（TARP）を含む、前臨床試験でさまざまな製品候補を開発しています。PDS0202、インフルエンザワクチン候補。
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.」